JP2016529253A5 - - Google Patents

Download PDF

Info

Publication number: JP2016529253A5
Authority: JP; Japan
Prior art keywords: chem; xaa; 8aib; seq; prevention
Prior art date: 2014-08-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016533923A

Other languages

English (en)

Japanese (ja)

Other versions

JP6599863B2 (ja

JP2016529253A (ja

Filing date

2014-08-14

Publication date

2017-08-10

2014-08-14 Application filed filed Critical

2014-08-14 Priority claimed from PCT/EP2014/067413 external-priority patent/WO2015022400A1/en

2016-09-23 Publication of JP2016529253A publication Critical patent/JP2016529253A/ja

2017-08-10 Publication of JP2016529253A5 publication Critical patent/JP2016529253A5/ja

2019-10-30 Application granted granted Critical

2019-10-30 Publication of JP6599863B2 publication Critical patent/JP6599863B2/ja

Status Active legal-status Critical Current

2034-08-14 Anticipated expiration legal-status Critical

Links

230000002265 prevention Effects 0.000 claims 20
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 8
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 8
230000009467 reduction Effects 0.000 claims 8
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 7
102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
108090000765 processed proteins & peptides Proteins 0.000 claims 6
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 5
229940024606 amino acid Drugs 0.000 claims 5
150000001413 amino acids Chemical class 0.000 claims 5
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 5
206010012601 diabetes mellitus Diseases 0.000 claims 5
208000008589 Obesity Diseases 0.000 claims 4
201000010099 disease Diseases 0.000 claims 4
235000020824 obesity Nutrition 0.000 claims 4
208000024172 Cardiovascular disease Diseases 0.000 claims 3
208000002705 Glucose Intolerance Diseases 0.000 claims 3
102000004877 Insulin Human genes 0.000 claims 3
108090001061 Insulin Proteins 0.000 claims 3
230000001154 acute effect Effects 0.000 claims 3
230000006872 improvement Effects 0.000 claims 3
229940125396 insulin Drugs 0.000 claims 3
239000013067 intermediate product Substances 0.000 claims 3
150000002632 lipids Chemical class 0.000 claims 3
201000009104 prediabetes syndrome Diseases 0.000 claims 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
201000006474 Brain Ischemia Diseases 0.000 claims 2
208000014644 Brain disease Diseases 0.000 claims 2
206010006550 Bulimia nervosa Diseases 0.000 claims 2
206010008120 Cerebral ischaemia Diseases 0.000 claims 2
208000011231 Crohn disease Diseases 0.000 claims 2
208000002249 Diabetes Complications Diseases 0.000 claims 2
206010012655 Diabetic complications Diseases 0.000 claims 2
208000030814 Eating disease Diseases 0.000 claims 2
208000019454 Feeding and Eating disease Diseases 0.000 claims 2
208000018522 Gastrointestinal disease Diseases 0.000 claims 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
150000001408 amides Chemical class 0.000 claims 2
230000036772 blood pressure Effects 0.000 claims 2
230000000747 cardiac effect Effects 0.000 claims 2
206010008118 cerebral infarction Diseases 0.000 claims 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
208000010877 cognitive disease Diseases 0.000 claims 2
235000014632 disordered eating Nutrition 0.000 claims 2
150000002148 esters Chemical class 0.000 claims 2
230000006870 function Effects 0.000 claims 2
230000004054 inflammatory process Effects 0.000 claims 2
201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
150000003839 salts Chemical class 0.000 claims 2
208000011580 syndromic disease Diseases 0.000 claims 2
230000009885 systemic effect Effects 0.000 claims 2
WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 1
OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 1
CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
-1 (8Aib Chemical class 0.000 claims 1
ACZFBYCNAVEFLC-YFKPBYRVSA-N (S)-3-(imidazol-5-yl)lactic acid Chemical compound OC(=O)[C@@H](O)CC1=CN=CN1 ACZFBYCNAVEFLC-YFKPBYRVSA-N 0.000 claims 1
FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
208000007848 Alcoholism Diseases 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
206010002383 Angina Pectoris Diseases 0.000 claims 1
102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
102000007592 Apolipoproteins Human genes 0.000 claims 1
108010071619 Apolipoproteins Proteins 0.000 claims 1
200000000007 Arterial disease Diseases 0.000 claims 1
206010003210 Arteriosclerosis Diseases 0.000 claims 1
201000001320 Atherosclerosis Diseases 0.000 claims 1
208000031729 Bacteremia Diseases 0.000 claims 1
206010007556 Cardiac failure acute Diseases 0.000 claims 1
206010007558 Cardiac failure chronic Diseases 0.000 claims 1
206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
208000014997 Crohn colitis Diseases 0.000 claims 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
229930195721 D-histidine Natural products 0.000 claims 1
206010052337 Diastolic dysfunction Diseases 0.000 claims 1
206010013654 Drug abuse Diseases 0.000 claims 1
208000032928 Dyslipidaemia Diseases 0.000 claims 1
208000007530 Essential hypertension Diseases 0.000 claims 1
206010064147 Gastrointestinal inflammation Diseases 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
206010020772 Hypertension Diseases 0.000 claims 1
206010058179 Hypertensive emergency Diseases 0.000 claims 1
206010021518 Impaired gastric emptying Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
206010022489 Insulin Resistance Diseases 0.000 claims 1
206010022562 Intermittent claudication Diseases 0.000 claims 1
102000007330 LDL Lipoproteins Human genes 0.000 claims 1
108010007622 LDL Lipoproteins Proteins 0.000 claims 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
208000017170 Lipid metabolism disease Diseases 0.000 claims 1
102000057248 Lipoprotein(a) Human genes 0.000 claims 1
108010033266 Lipoprotein(a) Proteins 0.000 claims 1
208000035180 MODY Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
206010038563 Reocclusion Diseases 0.000 claims 1
206010063837 Reperfusion injury Diseases 0.000 claims 1
208000017442 Retinal disease Diseases 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
206010040070 Septic Shock Diseases 0.000 claims 1
206010049416 Short-bowel syndrome Diseases 0.000 claims 1
208000007107 Stomach Ulcer Diseases 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
206010071436 Systolic dysfunction Diseases 0.000 claims 1
208000030886 Traumatic Brain injury Diseases 0.000 claims 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
206010046543 Urinary incontinence Diseases 0.000 claims 1
230000005856 abnormality Effects 0.000 claims 1
206010001584 alcohol abuse Diseases 0.000 claims 1
208000025746 alcohol use disease Diseases 0.000 claims 1
HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 1
239000000164 antipsychotic agent Substances 0.000 claims 1
230000006907 apoptotic process Effects 0.000 claims 1
230000036528 appetite Effects 0.000 claims 1
235000019789 appetite Nutrition 0.000 claims 1
230000006793 arrhythmia Effects 0.000 claims 1
206010003119 arrhythmia Diseases 0.000 claims 1
208000011775 arteriosclerosis disease Diseases 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
230000037396 body weight Effects 0.000 claims 1
230000003915 cell function Effects 0.000 claims 1
235000012000 cholesterol Nutrition 0.000 claims 1
208000029078 coronary artery disease Diseases 0.000 claims 1
230000003247 decreasing effect Effects 0.000 claims 1
208000010643 digestive system disease Diseases 0.000 claims 1
ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
201000006549 dyspepsia Diseases 0.000 claims 1
230000037406 food intake Effects 0.000 claims 1
235000012631 food intake Nutrition 0.000 claims 1
230000030135 gastric motility Effects 0.000 claims 1
201000005917 gastric ulcer Diseases 0.000 claims 1
208000018685 gastrointestinal system disease Diseases 0.000 claims 1
208000004104 gestational diabetes Diseases 0.000 claims 1
239000008103 glucose Substances 0.000 claims 1
208000019622 heart disease Diseases 0.000 claims 1
229960002885 histidine Drugs 0.000 claims 1
201000001421 hyperglycemia Diseases 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
230000028709 inflammatory response Effects 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
208000021156 intermittent vascular claudication Diseases 0.000 claims 1
208000017169 kidney disease Diseases 0.000 claims 1
201000006370 kidney failure Diseases 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
201000005857 malignant hypertension Diseases 0.000 claims 1
201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 1
230000004060 metabolic process Effects 0.000 claims 1
230000004899 motility Effects 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
208000010125 myocardial infarction Diseases 0.000 claims 1
208000037891 myocardial injury Diseases 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
230000000626 neurodegenerative effect Effects 0.000 claims 1
201000001119 neuropathy Diseases 0.000 claims 1
230000007823 neuropathy Effects 0.000 claims 1
230000000414 obstructive effect Effects 0.000 claims 1
201000008482 osteoarthritis Diseases 0.000 claims 1
239000002245 particle Substances 0.000 claims 1
208000027232 peripheral nervous system disease Diseases 0.000 claims 1
208000033808 peripheral neuropathy Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000036470 plasma concentration Effects 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
230000033764 rhythmic process Effects 0.000 claims 1
230000036186 satiety Effects 0.000 claims 1
235000019627 satiety Nutrition 0.000 claims 1
230000035945 sensitivity Effects 0.000 claims 1
230000036303 septic shock Effects 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
201000002859 sleep apnea Diseases 0.000 claims 1
230000006641 stabilisation Effects 0.000 claims 1
238000011105 stabilization Methods 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
206010042772 syncope Diseases 0.000 claims 1
230000035488 systolic blood pressure Effects 0.000 claims 1
150000003626 triacylglycerols Chemical class 0.000 claims 1
208000019553 vascular disease Diseases 0.000 claims 1
FCGQPGJZMYSYCJ-UHFFFAOYSA-N CC(C1CCC(CNN)CC1)=O Chemical compound CC(C1CCC(CNN)CC1)=O FCGQPGJZMYSYCJ-UHFFFAOYSA-N 0.000 description 2
0 CC(CCNI)OCCC(OC(C)(*)CC(N)=O)=* Chemical compound CC(CCNI)OCCC(OC(C)(*)CC(N)=O)=* 0.000 description 2
LEUFZGSWQSPVGT-UHFFFAOYSA-N CC(C(CS(O)(=O)=O)NN)=O Chemical compound CC(C(CS(O)(=O)=O)NN)=O LEUFZGSWQSPVGT-UHFFFAOYSA-N 0.000 description 1
KCEHUPIXDRDKQS-UHFFFAOYSA-N NC(CCC(C(O)=O)NN)=O Chemical compound NC(CCC(C(O)=O)NN)=O KCEHUPIXDRDKQS-UHFFFAOYSA-N 0.000 description 1

JP2016533923A 2013-08-15 2014-08-14 Ｇｌｐ−１誘導体及びその使用 Active JP6599863B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361866169P	2013-08-15	2013-08-15
EP13180558.2		2013-08-15
US61/866,169		2013-08-15
EP13180558		2013-08-15
PCT/EP2014/067413 WO2015022400A1 (en)	2013-08-15	2014-08-14	Glp-1 derivatives, and uses thereof

Publications (3)

Publication Number	Publication Date
JP2016529253A JP2016529253A (ja)	2016-09-23
JP2016529253A5 true JP2016529253A5 (2)	2017-08-10
JP6599863B2 JP6599863B2 (ja)	2019-10-30

Family

ID=48985644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016533923A Active JP6599863B2 (ja)	2013-08-15	2014-08-14	Ｇｌｐ−１誘導体及びその使用

Country Status (5)

Country	Link
US (1)	US10266577B2 (2)
EP (1)	EP3033112B1 (2)
JP (1)	JP6599863B2 (2)
CN (1)	CN105451776B (2)
WO (1)	WO2015022400A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
WO2017005765A1 (en) *	2015-07-06	2017-01-12	Novo Nordisk A/S	Novel peptides and peptide derivatives and uses thereof
CN108697768B (zh)	2015-12-23	2022-07-22	约翰霍普金斯大学	长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
ES2828526T3 (es)	2016-11-07	2021-05-26	Novo Nordisk As	Esteres activos DCHBS de compuestos PEG y sus usos
CN109248323B (zh) *	2017-07-14	2023-09-08	杭州先为达生物科技有限公司	酰化的glp-1衍生物
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
EP3728303A1 (en) *	2017-12-19	2020-10-28	Novo Nordisk A/S	Solubility of glp-1 peptide
MX2020010505A (es)	2018-04-05	2021-01-15	Sun Pharmaceutical Ind Ltd	Analogos novedosos de glp-1.
CN113214381B (zh) *	2018-04-19	2024-01-19	杭州先为达生物科技股份有限公司	酰化的glp-1衍生物
WO2019200594A1 (zh) *	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
US11633459B2 (en)	2018-05-04	2023-04-25	Novo Nordisk A/S	GIP derivatives and uses thereof
WO2019243502A1 (en)	2018-06-21	2019-12-26	Novo Nordisk A/S	Novel compounds for treatment of obesity
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
CN110759991B (zh) *	2019-12-09	2023-01-13	江苏师范大学	吉非罗齐-非洲爪蟾胰高血糖素样肽-1衍生物及其应用
CN114729060B (zh) *	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
KR20230160321A (ko) *	2021-03-24	2023-11-23	브리스톨-마이어스 스큅 컴퍼니	면역조정제
CN116891522B (zh) *	2022-04-01	2024-05-14	南京知和医药科技有限公司	一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
WO2024179606A1 (zh) *	2023-03-02	2024-09-06	甘李药业股份有限公司	一种glp-1化合物的医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
AU2002308706A1 (en)	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
PL209734B1 (pl)	2002-02-20	2011-10-31	Emisphere Tech Inc	Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
BR122019021416A2 (2)	2003-09-19	2019-12-21
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
US9766217B2 (en)	2006-09-08	2017-09-19	Novo Nordisk A/S	Methods of optimizing chromatographic separation of polypeptides
JP6006118B2 (ja)	2009-12-16	2016-10-12	ノヴォノルディスクアー／エス	Ｇｌｐ−１アナログ及び誘導体
JP6039569B2 (ja)	2010-11-09	2016-12-07	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
EP2846823B1 (en) *	2012-05-08	2019-12-04	Novo Nordisk A/S	Double-acylated glp-1 derivatives

2014
- 2014-08-14 EP EP14752614.9A patent/EP3033112B1/en active Active
- 2014-08-14 US US14/909,543 patent/US10266577B2/en active Active
- 2014-08-14 JP JP2016533923A patent/JP6599863B2/ja active Active
- 2014-08-14 WO PCT/EP2014/067413 patent/WO2015022400A1/en not_active Ceased
- 2014-08-14 CN CN201480045339.1A patent/CN105451776B/zh active Active

Publication	Publication Date	Title
JP2016529253A5 (2)	2017-08-10
JP2016523243A5 (2)	2017-06-22
JP2017105819A5 (2)	2017-08-24
JP2018505859A5 (2)	2019-02-07
JP2019513126A5 (2)	2020-04-09
JP2014501712A5 (2)	2014-11-06
JP2013543853A5 (2)	2014-11-06
JP2014529629A5 (2)	2015-10-01
RU2013148921A (ru)	2015-05-20	Дважды ацилированные производные glp-1
Melson et al.	2023	Future therapies for obesity
AU2011247824B2 (en)	2014-02-13	Glucagon-like peptide-1 analogue and use thereof
JP6379300B2 (ja)	2018-08-22	ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
JP2023071869A (ja)	2023-05-23	グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
JP2015517477A5 (2)	2016-06-09
JP2015517478A5 (2)	2016-06-09
WO2013004983A1 (en)	2013-01-10	Novel compounds and their effects on feeding behaviour
CN107205949A (zh)	2017-09-26	包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
US20100305139A1 (en)	2010-12-02	Method of treating abnormal lipid metabolism
JP2007519642A5 (2)	2008-03-06
Jin et al.	2024	GPCRs involved in metabolic diseases: pharmacotherapeutic development updates
JP2012529434A5 (2)	2013-07-18
JP2013510167A (ja)	2013-03-21	ストレスコピン様ペプチドによる心不全の治療方法
Xu et al.	2024	Myeloid-derived growth factor and its effects on cardiovascular and metabolic diseases
CN107987152A (zh)	2018-05-04	霉酚酸-非洲爪蟾胰高血糖素样肽-1缀合肽及其用途
JP2011525895A5 (2)	2012-06-28